| 生物活性 |
Budigalimab (ABBV 181; PR 1648817) is a humanized, recombinant IgG1 monoclonal antibody targeting programmed cell death 1 (PD-1) receptor. Budigalimab has an Fc mutation that reduces the inhibition of Fc receptor interactions and effector factors. Budigalimab can block the binding of PD-1 and PD-L1, which has anti-tumor activity. Budigalimab can be used in the study of solid tumors.
|
|---|---|
| 分子量 |
144.76 kDa
|
| CAS号 |
2098225-93-3
|
| 中文名称 |
布格利单抗
|
| 运输条件 |
Shipping with dry ice.
|
| 储存方式 |
Store at -20˚C
|
纯度： 99%
关注我们
获得KKL MED 最新资讯
咨询热线：
400-881-9290
Data Sheet